CD20-positive primary central nervus system lymphoma, or relapsed CD20-positive non-Hodgkin lymphoma in CNS alone
Conditions
Interventions
Day 1: Intraventricle injection of 10 mg (1 ml) of rituximab and 8 ml of autologous serum via Ommaya reservoir. Day 3: Intraventricle injection of 40 mg (4 ml) of rituximab and 8 ml of autologous ser
Sponsors
Division of Hematology, University of Tsukuba
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: With written informed concent, relapsed or primary refractory CD20-positive primary CNS lymphoma, or relapsed non-Hodgkin lymphoma in CNS alone, which was treated with chemotherapy of multiple drugs including high dose methotrexate or high dose AraC, or with autologous hematopoietic cell transplantation (AHCT). The patient must be considered but are not candidate for radiation or other therapies because these therapies are considered to be ineffective or bring serious side effects, or the patient did not consent to these therapies. If the patient has not been treated with AHCT, the modality must be considered but is concluded as not feasible because of the patient's age, comobidities or rejection.
Exclusion criteria
Exclusion criteria: Poor general status (ECOG Performance status 3 or 4). Inablity in understanding of the therapy even due to the primary disease. Lesions outside of central nervas system which are uncontroled or less than three months from shrinking.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response | — |
Countries
Japan
Outcome results
None listed